Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025 4:14 PM ESTCHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer
Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million
LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025
Conference call today at 5:00 p.m. Eastern Standard Time
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights.
In Q3 2025, we gained... More



